Pfizer (PFE)

• Market cap: $141B
• 1 day: -4.69%
• 5 days: -7.19%
• 1 month: -15.76%
• 3 months: -13.62%
• 6 months: -13.95%
• Year to date: -16.58%
• 1 year: -17.85%
• 5 years: -33.48%
• 10 years: -18.21%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Employees: 88,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

26% more funds holding in top 10

Funds holding in top 10: 31 [Q2] → 39 (+8) [Q3]

3% more repeat investments, than reductions

Existing positions increased: 1,185 | Existing positions reduced: 1,149

1% less capital invested

Capital invested by funds: $108B [Q2] → $106B (-$1.13B) [Q3]

1% less funds holding

Funds holding: 2,820 [Q2] → 2,790 (-30) [Q3]

2.71% less ownership

Funds ownership: 67.32% [Q2] → 64.62% (-2.71%) [Q3]

14% less first-time investments, than exits

New positions opened: 185 | Existing positions closed: 215

38% less call options, than puts

Call options by funds: $2.51B | Put options by funds: $4.05B

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $25 1% upside
• Avg. target: $41 65% upside
• High target: $45 81% upside

8 analyst ratings

• positive: 6 75%
• neutral: 1 13%
• negative: 1 13%

Wolfe Research Alexandria Hammond 0% 1-year accuracy 0 / 1 met price target	1% upside $25	Underperform Initiated	15 Nov 2024
Cantor Fitzgerald Louise Chen 35% 1-year accuracy 56 / 161 met price target	81% upside $45	Overweight Reiterated	25 Oct 2024
Cantor Fitzgerald Louise Chen 35% 1-year accuracy 56 / 161 met price target	81% upside $45	Overweight Reiterated	23 Oct 2024
Bernstein	29% upside $32	Market Perform Initiated	17 Oct 2024
Cantor Fitzgerald Louise Chen 35% 1-year accuracy 56 / 161 met price target	81% upside $45	Overweight Reiterated	3 Oct 2024